Pharmacological Tolerance in the Treatment of Fragile X Syndrome

With a $90,000 grant from FRAXA Research Foundation over 2018-2020, Dr. Patrick McCamphill, postdoctoral fellow in Dr. Mark Bear’s lab at Massachusetts Institute of Technology (MIT), is investigating drug tolerance to mGluR5 antagonists, arbaclofen, and other potential Fragile X treatments. He is also exploring ways to overcome it.

Patrick McCamphill
$90,000 Grant
Patrick McCamphill, PhD
FRAXA Postdoctoral Fellow
Mark Bear, PhD
Principal Investigator
Massachusetts Institute of Technology (MIT)
2018-2020 FRAXA Research Grant
$90,000 over 3 Years

by Patrick McCamphill

Several years ago, many families across the U.S. and in a number of countries participated in large-scale clinical trials of experimental Fragile X treatments from Novartis, Roche, and Seaside Therapeutics. While these trials ultimately failed to demonstrate that the treatments worked, many of these families reported exciting improvements.

Why did these trials fail? One potential explanation is that tolerance rapidly develops to the drugs, so they lose their effectiveness. Indeed, some caregiver reports have suggested some early improvement that did not continue for the length of treatment.

mGluR5 Antagonists

In 2005, FRAXA Investigator Dr. Robert Bauchwitz and colleagues showed that an experimental compound which blocks mGluR5 protected Fragile X mice from seizures. But this effect faded quickly with chronic treatment, suggesting that the mice developed tolerance to the drug. With a grant from FRAXA over 2016-2017, our lab at MIT found preliminary evidence confirming Dr. Bauchwitz’s result. The first goal of our new study is to understand this drug tolerance to mGluR5 antagonists in Fragile X mice and to explore approaches to avoid or reduce it.

Arbaclofen and GSK3 Inhibitors

We will also determine if tolerance develops to a range of other drugs which show promise for Fragile X, including arbaclofen (a GABA-B receptor agonist) and GSK3 inhibitors. Arbaclofen, code-named STX209, was tested unsuccessfully by Seaside Therapeutics in large-scale clinical trials for children with Fragile X, so it will be quite important to understand if tolerance was a factor in those results. GSK3 inhibitors, including lithium, have successfully reversed Fragile X symptoms in animal studies.

Development of tolerance may explain the disappointing clinical results obtained to date with a range of drugs. The possibility of tolerance has been relatively neglected in preclinical studies to date, so we propose to compare durable efficacy of three different pharmacological treatments that target different stages of the aberrant signaling pathways in Fragile X mice. We will also investigate the potential problem of cross-tolerance, when taking one drug produces tolerance to another similar drug, and look for ways to avoid it using combinations of various drugs to maintain benefits over the long term.

Patrick McCamphill

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Share via
Copy link